Adherence to Cholinesterase Inhibitors in Alzheimer’s Disease: A Review

Roseanna Brady\textsuperscript{a}    John Weinman\textsuperscript{b}
\textsuperscript{a}Atlantis Healthcare and \textsuperscript{b}Institute of Psychiatry, Kings College London, London, UK

Key Words
Alzheimer’s disease · Medication adherence · Medication persistence · Medication non-adherence

Abstract
\textbf{Background/Aims}: Treatment adherence is a major problem in numerous medical conditions, and is a particular challenge in patients with Alzheimer’s disease (AD). \textbf{Methods}: This non-systematic review summarises the current literature on factors that affect adherence to cholinesterase inhibitors, the mainstay of AD treatment. Articles listed on PubMed and published during the last 10 years were included. \textbf{Results}: Intentional factors affecting adherence include patient, caregiver and prescriber beliefs about therapies and the disease itself. Unintentional factors include tolerability, physical limitations of the patient and caregiver burden. Interventions aiming to improve adherence include educational programmes and new drug delivery methods. \textbf{Conclusion}: Due to the high level of caregiver involvement in the care of patients with AD, strategies that address caregiver concerns may improve adherence.

Introduction

The effectiveness of any treatment is dependent upon the required medications being administered as prescribed. However, treatment adherence (or compliance), defined as ‘the extent to which a patient’s behaviour matches agreed recommendations from the prescriber’ [1], is a major problem in the management of many medical conditions [1, 2].

Alzheimer’s disease (AD) is the most common cause of dementia worldwide, with global prevalence estimated to be as high as 24 million, and predicted to double every 20 years through to 2040 [3, 4]. AD is a chronic neurodegenerative condition characterised by a progressive deterioration of cognitive function [3, 4]. From onset, AD causes progressive deficits in memory, language, judgement, decision making, orientation and learning [3, 4].
The mainstays of treatment for the relief of mild-to-moderate AD symptoms are the cholinesterase inhibitors (ChEIs) donepezil, galantamine and rivastigmine [5, 6]. Sustained use of these agents for 3 or more months may delay the worsening of cognitive, functional and behavioural symptoms of AD [5, 7]. However, treatment management is a major challenge in AD, with non-adherence to treatment often a barrier to effective therapy [8, 9].

The aim of this non-systematic literature review is to highlight some of the challenges associated with adherence to ChEIs, since these are by far the most commonly prescribed medications for patients with AD, and to discuss strategies addressing these issues in clinical practice.

Methods

A search of the online PubMed literature database (http://www.ncbi.nlm.nih.gov/pubmed) was performed in December 2011 using combinations of the following terms: Alzheimer’s disease; cholinesterase inhibitors; adherence; compliance; persistence; caregiver, and non-adherence. In order to focus the search on up-to-date information, articles were limited to those published in the last 10 years. Only articles published in the English language were included. The search results were then manually assessed for relevance using the titles and abstracts of the publications. Further relevant references were selected from the bibliographies of identified papers. A summary of the key studies can be found in table 1.

Treatment of AD Symptoms

ChEIs cannot reverse AD or prevent its natural progression, instead they provide relief from symptoms [5, 10]. With all three approved agents (donepezil, galantamine and rivastigmine), modest improvements in measures of disease severity last for approximately 6 months, but seldom result in recovery of lost function [5, 7]. Rigorous reviews of clinical trial data for each of the three available oral ChEIs show that they all reduce the rate of cognitive function decline and dementia severity, and improve performance in activities of daily living in people with mild-to-moderate AD [10–12]. However, functional capacities lost (e.g. the ability to manage finances or drive) are rarely recovered [5, 7, 10–12]. Owing to its dual action on both acetylcholinesterase and butyrylcholinesterase, it has been suggested that rivastigmine may also reduce behavioural symptoms in mild- to-moderate AD (galantamine and donepezil act solely on acetylcholinesterase) [13].

Treatment Adherence in AD

The Importance of Treatment Adherence in AD

AD has a major impact on the quality of life (QoL) of both the patient and the caregiver [14–16]. Given the short life expectancy following a diagnosis of AD (median 3–8 years [17]), and the progressive nature of the disease, treatments that stabilise symptoms or delay their progression, even for 6–12 months, can have important benefits on QoL for patients and their caregivers [14, 15]. An observational study of 445 patients with AD found that the use of ChEIs for at least 1 year was associated with a decreased risk of rapid cognitive deterioration and institutionalisation [18]. It follows that patients who manage to adhere to AD therapies for longer have a greater chance of slowing or delaying progression of their symptoms and increasing their QoL [8]. Furthermore, a delay in institutionalisation of patients may also lead to savings in healthcare costs [19, 20].
<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Main study endpoint(s)</th>
<th>Study results</th>
<th>Comments/conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amuah et al. 2010 [22]</td>
<td>Retrospective analysis of administrative health database in Saskatchewan, Canada</td>
<td>Persistence: time in days from the date of expected initiation to date of expected discontinuation; Discontinuation: prescription not refilled within 60 days of expected depletion</td>
<td>n = 1,080 Over 40 months, 84% discontinued therapy 50% of patients discontinued therapy within 7 months 1-year risk of discontinuation: 66.4% (95% CI 63.5, 69.3) Increased risk for discontinuation: being female; low MMSE score; no social assistance; paying ≥65% prescription costs Decreased risk for discontinuation: frequent physician visits; higher chronic disease scores; FAQ score ≥9</td>
<td>Discontinuation based on 60 days treatment gap Discontinuation rate was relatively high Discontinuation rates were associated with clinical, socioeconomic and practice factors Evaluation based on drug dispensation and not drug administration</td>
</tr>
<tr>
<td>Blais et al. 2009 [23]</td>
<td>Analysis of administrative healthcare database in Québec, Canada</td>
<td>MPR (sum of drug supply days between the first and last filled prescriptions divided by the number of days between fill dates)</td>
<td>n = 28,405 Adherence (all three agents): 93.5% (95% CI 93.1, 93.8) Donepezil (n = 19,031): 94.5% (95% CI 94.1, 95.0) Rivastigmine (n = 3,791): 99.2% (95% CI 97.8, 100.6) Galantamine (n = 3,450): 96.5% (95% CI 95.6, 97.4)</td>
<td>Evaluation based on drug dispensation and not drug administration Weekly pill boxes used by 65% of patients Home delivery service of medication used by 79% of patients</td>
</tr>
<tr>
<td>Borah et al. 2010 [21]</td>
<td>Retrospective analysis of managed-healthcare plan in the US</td>
<td>MPR (total days’ supply during 12-month follow-up/365 × 100) Adherence defined as MPR ≥80%</td>
<td>n = 3,091 Adherence: 58.2% Mean (SD) duration of therapy: 118.7 (79.8) days Discontinued oral AD therapy: 40.0%</td>
<td>Adherence was associated with: being male; aged ≥86 years; greater overall daily pill burden; lower formulary tier AD medication (i.e. lower cost) Evaluation based on drug dispensation and not drug administration</td>
</tr>
<tr>
<td>Gadzhanova et al., 2010 [24]</td>
<td>Retrospective cohort study based on pharmacy claims for ChEI</td>
<td>Time to discontinuation (treatment refill gap of ≥99 days)</td>
<td>n = 10,088 Discontinuation at 6 months: 45% Median treatment duration: donepezil (n = 6,705), 199 days (95% CI 182, 208); galantamine (n = 2,989), 233 days (95% CI 212, 259); rivastigmine (n = 394), 219 days (95% CI 176, 260) 32% restarted therapy before the end of the study</td>
<td>Treatment duration was similar between the three agents Re-start rate suggests that non-persistence is a problem rather than therapeutic failure Community-dwelling residents discontinued therapy earlier than those in residential care Based on 99 days treatment gap Evaluation based on drug dispensation and not drug administration</td>
</tr>
<tr>
<td>Study</td>
<td>Study design</td>
<td>Main study endpoint(s)</td>
<td>Study results</td>
<td>Comments/conclusions</td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>------------------------</td>
<td>---------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Gardette et al. 2010 [60]</td>
<td>Cohort study of ambulatory community-dwelling patients with AD, with MMSE score of 10–26, and an informal caregiver</td>
<td>Not clearly defined</td>
<td>n = 611&lt;br&gt;377 patients completed the 2-year study&lt;br&gt;At 2 years, 100 patients had either switched ChEI or discontinued therapy&lt;br&gt;Median time of discontinuation/switching: 8.5 months</td>
<td>High level of caregiver involvement&lt;br&gt;Independent factors associated with switching to a different ChEI were: an ineffective ChEI dose; rapid cognitive decline; hospitalisation unrelated to AD, and an anxiety score ≥4 points on the NPI</td>
</tr>
<tr>
<td>Herrmann et al. 2009 [25]</td>
<td>Observational administrative health database study in patients aged ≥65 years who received a new prescription for an oral ChEI between February and May 2006</td>
<td>Persistence: (i) missed days of medication less than twice the number of days on the previous prescription; (ii) breaks in prescriptions ≤30 days; (iii) missed days allowed per year ≤120 days</td>
<td>n = 5,622&lt;br&gt;1-year persistence: galantamine ER, 53.6% (95% CI 50.7, 56.5); donepezil, 45.9% (95% CI 43, 48.8); rivastigmine, 40.2% (95% CI 37.3, 43.1)&lt;br&gt;Average days of therapy: galantamine ER, 293 days; rivastigmine, 272 days; donepezil, 287 days</td>
<td>Persistence based on 30 days treatment gap&lt;br&gt;Both galantamine ER and donepezil were administered once daily; oral rivastigmine was administered twice daily&lt;br&gt;Evaluation based on drug dispensation and not drug administration</td>
</tr>
<tr>
<td>Kroger et al. 2010 [26]</td>
<td>Retrospective cohort study of pharmacy records in the Netherlands&lt;br&gt;Patients: aged ≥50 years with first dispensing of rivastigmine or galantamine between July 1998 and January 2008 and ≥1 year of exposure history</td>
<td>Discontinuation based on 30 days treatment gap</td>
<td>n = 3,369&lt;br&gt;Treatment discontinuation increased from 8.5% after 1 month to 30.8% after 6 months and 59.0% after 3 years</td>
<td>Discontinuation based on 30 days treatment gap&lt;br&gt;Evaluation based on drug dispensation and not drug administration</td>
</tr>
<tr>
<td>Massoud et al. 2008 [27]</td>
<td>Analysis of administrative healthcare database in Québec, Canada&lt;br&gt;Patients: claimants of ≥1 dispensation for a ChEI between April 1, 2000 and June 30, 2003</td>
<td>Discontinuation: non-renewal of any ChEI before the end of the grace period (50% of the prescription duration) that was added to the end of the prescription&lt;br&gt;Persistence was estimated using Kaplan-Meier analysis</td>
<td>n = 18,748&lt;br&gt;Taking medication 216 days after initiation: 50%&lt;br&gt;Taking medication at 12 months: 40%</td>
<td>Risk of discontinuation significantly higher: for donepezil compared with galantamine; aged ≥80 years compared with aged &lt;70 years, and for those who received drug from a GP rather than another prescriber&lt;br&gt;Evaluation based on drug dispensation and not drug administration</td>
</tr>
<tr>
<td>Mucha et al. 2008 [28]</td>
<td>Retrospective analysis of administrative claims database&lt;br&gt;Patients: aged ≥65 years, newly prescribed a ChEI for AD; ≥1 claim for the same agent between January 1, 2001 and December 31, 2003</td>
<td>MPR: number of days of index drug supplied/365&lt;br&gt;Non-persistence: a gap of ≥30 days in therapy during the 12-month follow-up</td>
<td>n = 3,177&lt;br&gt;Mean (SD) MPR: donepezil, 0.74 (0.26); galantamine, 0.74 (0.26); rivastigmine, 0.71 (0.27)&lt;br&gt;Non-persistence: donepezil, 63.5%; galantamine, 63.7%; rivastigmine, 68.0%</td>
<td>Evaluation based on drug dispensation and not drug administration&lt;br&gt;Rivastigmine not approved in the US until late February 2001</td>
</tr>
<tr>
<td>Pariente et al. 2010 [29]</td>
<td>Retrospective cohort analysis of a French reimbursement database&lt;br&gt;Patients: initiating oral ChEI treatment between January 1, 2004 and December 31, 2005 with 1 year of follow-up data</td>
<td>Persistence: on-going treatment without dispensing interval &gt;60 consecutive days during the 12 months following treatment initiation</td>
<td>n = 942&lt;br&gt;1-year persistence: 43.5%</td>
<td>Persistence was lower in patients aged ≥80 years and higher in patients using antidepressants at ChEI treatment initiation compared with comparator groups&lt;br&gt;Evaluation based on drug dispensation and not drug administration</td>
</tr>
</tbody>
</table>
Table 1 (continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Main study endpoint(s)</th>
<th>Study results</th>
<th>Comments/conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roe et al. 2002 [30]</td>
<td>Analysis of pharmacy claims data Patients: new users of donepezil aged 65–94 years</td>
<td>Probability of new user continuing donepezil treatment at a given time point</td>
<td>90 days: 0.797 (95% CI ±0.103) 180 days: 0.627 (95% CI ±0.124)</td>
<td>13.9% of those who continued donepezil therapy for ≥180 days showed gaps in treatment of ≥6 weeks Evaluation based on drug dispensation and not drug administration</td>
</tr>
<tr>
<td>Schwalbe et al. 2010 [33]</td>
<td>Community-based cohort analysis in Germany Patients: ambulatory patients diagnosed with AD and receiving anti-dementia drugsa</td>
<td>Compliance: percentage of days with correctly administered doses of medication (monitored using MEMS)</td>
<td>n = 31 Median daily compliance: 94% (IQR 48–99%) Median compliance decreased by 7% from month 1 to month 6 10 patients (32%; 95% CI 17, 51) were ≥1 month non-compliant</td>
<td>Possible overestimation from ‘curiosity events’ (patient opens the container without taking the drug or takes the incorrect number of tablets) Measured drug access by patients (although actual administration of correct dose to patient could not be verified)</td>
</tr>
<tr>
<td>Singh et al. 2005 [31]</td>
<td>Analysis of a large State Medicaid programme Patients: newly initiated on rivastigmine or donepezil from April 2000 until December 31, 2002</td>
<td>Discontinuation: a drug switch or no prescription refill within 60 days of estimated completion of prior prescription</td>
<td>n = 17,742 Discontinuation: donepezil, 10,186 patients (67.3%); rivastigmine, 1,586 (60.7%) Median time to treatment discontinuation: donepezil, 120 days; rivastigmine, 135 days</td>
<td>Discontinuation based on 60 days treatment gap Evaluation based on drug dispensation and not drug administration</td>
</tr>
<tr>
<td>Suh et al. 2005 [32]</td>
<td>12-month retrospective analysis of longitudinal research databases including data from pharmacy and medical services Patients: aged ≥65 years with newly diagnosed AD and a filled prescription for rivastigmine or donepezil between January 1, 1999 and December 31, 2002</td>
<td>Persistence: prescription refill within 60 days of estimated completion of prior prescription</td>
<td>Persistence: rivastigmine, 234 days (median 312); donepezil, 235 days (median 315)</td>
<td>Persistence based on 60 days treatment gap Evaluation based on drug dispensation and not drug administration</td>
</tr>
</tbody>
</table>

CI = Confidence interval; ER = extended release; FAQ = Functional Activities Questionnaire; IQR = interquartile range; MEMS = medication event monitoring system; MMSE = Mini Mental State Examination; MPR = medication possession ratio; NPI = Neuropsychiatric Inventory; SD = standard deviation.

a Included: donepezil, rivastigmine, galantamine and memantine.
Studies Investigating Treatment Adherence in AD

Published data on treatment adherence and persistence (the length of time from initiation to discontinuation of treatment) in AD reveal conflicting results. In part, this may be owing to different methodological processes, such as the length of time taken to signify treatment discontinuation (e.g. 30, 60 or 90 days between prescription refills) or the environmental settings in which adherence has been studied (Table 1). Many studies investigating treatment adherence or persistence in patients with AD have been performed using retrospective analyses of administrative health databases or pharmacy claims [21–32]. It should be noted that in all of these studies, evaluation of adherence is based on drug dispensation and not actual drug intake by the patient.

In one retrospective analysis of a managed healthcare plan in the US between 2006 and 2008, only 58.2% of the 3,091 patients with AD (n = 31) using an electronic Medication Events Monitoring System (MEMS). The MEMS device consisted of a vial with a microprocessor in the lid which recorded the time (date, hour and minute) of every opening. Daily compliance served as primary outcome measure and was defined as the percentage of days with correctly administered doses of medication. The graph shows compliant months (daily compliance ≥80%, white bars) and non-compliant months (daily compliance <80%, grey bars) for all 31 patients. Patients 11 and 31 participated in the study for 5 months only.

**Fig. 1.** An example of intra-individual differences in adherence to treatment in patients with AD (reproduced with permission from Schwalbe et al. [33]). Compliance was assessed over 6 months in a cohort of ambulatory patients with AD (n = 31) using an electronic Medication Events Monitoring System (MEMS). The MEMS device consisted of a vial with a microprocessor in the lid which recorded the time (date, hour and minute) of every opening. Daily compliance served as primary outcome measure and was defined as the percentage of days with correctly administered doses of medication. The graph shows compliant months (daily compliance ≥80%, white bars) and non-compliant months (daily compliance <80%, grey bars) for all 31 patients. Patients 11 and 31 participated in the study for 5 months only.
In a recent study aimed at assessing actual medication administration/intake, adherence over a period of 6 months was assessed in a small cohort (n = 31) of ambulatory patients with AD using electronic monitoring (a medication vial with a microprocessor in the lid recording the time of every opening) [33]. On average, median compliance to ChEIs was 94% (range 49–99%) but was variable between patients, with 10 patients (32%) <80% compliant for a period of at least 1 month out of the 6 months studied (fig. 1) [33]. This study highlights that adherence rates may differ significantly between individual patients with AD.

Persistence is reported to be a particular problem in AD [8], perhaps more so than is adherence. Indeed, two treatment reviews performed in Canada assessing oral ChEIs showed that only 40–54% of patients achieved persistence at 12 months after initiation of therapy [25, 27]. Additionally, in a French study, 1-year persistence of ChEI treatment was estimated at 45.3% of 942 patients. The authors concluded that to optimise persistence with ChEIs, patients presenting with more severe symptoms and/or those aged over 80 years should be especially monitored [29].

In summary, evidence reported in the literature to date indicates that although day-to-day adherence to ChEIs can sometimes be high, there is a great deal of intra-individual and inter-study variation. In addition, persistence with medications over time may be poor. Understanding the reasons for poor treatment adherence and persistence in patients with AD is crucial for determining effective strategies to address and improve outcomes of this problem.

### Determinants of Non-Adherence in AD

As treatment adherence is presently suboptimal in AD, the potential benefits of the available effective therapies are not being fully experienced, either by patients or caregivers [8]. Non-adherence to treatment can either occur as the result of a considered deliberate decision (intentional non-adherence) or can happen unintentionally (unintentional non-adherence) due to misunderstanding instructions, forgetfulness or unforeseen circumstances. Furthermore, within these categories, patient, caregiver and prescriber factors all exert influences on medication adherence (fig. 2) [1].

#### Intentional Non-Adherence

Intentional non-adherence is based on patient, caregiver or prescriber beliefs and perceptions about the illness and the treatments available for it. It is clear from the literature that few studies have investigated illness perceptions specifically in dementia or AD, and none have specifically investigated the impact of illness perceptions on treatment adherence [34–36].

**Patient Beliefs**

Patient understanding and beliefs about their illness may impact on their likelihood both to seek help for their symptoms and also to adhere to any recommended therapies. A review of qualitative research proposed that three phases of decision making are important regarding medication adherence in older people: faith in the prescriber’s ability to correctly diagnose and select treatment; testing of the effectiveness of the medication on symptom relief and adverse effects, and patients’ beliefs about the illness itself [37]. Any one of these can influence attitudes to treatment and adherence. For example, in one study, patients with mild-to-moderate AD did not perceive themselves as being ill and assessed their condition as stable or improving [35]; such misconceptions may alter a patient’s acceptance for taking medications. As such, there is clearly a need to educate patients both about the disease itself and available treatment options.
Along with beliefs about the disease itself, there is an expectation among patients with AD (along with their caregivers) for symptom improvement following treatment, and disease stabilisation is not necessarily valued. This may discourage persistence with any medications, such as ChEIs, that treat only the symptoms of disease [5, 8].

**Caregiver Beliefs**

Cultural beliefs may also impact on treatment decisions [38, 39]. One study showed that Hispanic and Chinese caregivers were more likely than caregivers from other cultural groups to believe that AD is part of the normal ageing process – such attitudes may delay help seeking by these caregivers, the patients and other family members [39].

Another study specific to AD assessed the attitudes of first-degree relatives (not necessarily caregivers) towards future availability of suitable treatments for the symptoms of AD [36]. The results suggested a positive attitude to AD pharmacological treatments in general. As ChEIs cannot reverse the disease, it is very important that caregiver expectations of treatment outcome are realistic. Indeed, a large perception difference has been reported between physicians and caregivers of patients with AD regarding many aspects of care (including disease aetiology, pathogenesis, dosage and treatment recommendations and adherence) [40]. This highlights the need to improve the communication process between prescribers and caregivers in order to optimise clinical management of AD, which may include increased adherence to effective therapies [40]. Furthermore, in a recent study, overall caregiver satisfaction with treatment for AD did not correlate with patient compliance to treatment, but it did correlate with the changes in patient’s cognitive impairment, a factor that also influences caregiver’s burden [14]. It therefore follows that improvements in adherence to ChEIs would have a positive impact on caregiver burden.

**Fig. 2.** Possible predictors for treatment non-adherence in patients with AD.
Prescriber Beliefs

In addition to patient and caregiver attitudes, the attitudes and beliefs of prescribing physicians are also likely to impact on treatment adherence and persistence in AD. Massoud et al. [41] suggested that physicians may not persist with AD treatments because they do not regard stabilisation of the disease as a great benefit. However, as discussed previously, in a condition such as AD, where there is a steady deterioration in a patient’s cognitive and functional abilities, treatments that stabilise symptoms or delay progression, even for 6–12 months, can have important benefits on QoL for both patients and their caregivers [8, 14, 15]. Physician education on the value of disease stabilisation and symptom relief, to both patients and caregivers, may therefore help to relieve caregiver burden.

Unintentional Non-Adherence

The chronic nature of AD and the associated deficits in cognitive and physical functions make patients particularly susceptible to treatment non-adherence [8]. Other factors involved in unintentional non-adherence include those related to the medication itself, as well as caregiver and prescriber factors.

Patient Factors

In the early stages of AD, patients are involved in the management of their own medications [42]. However, as people age and the disease progresses, they have increasing physical, visual and cognitive limitations that relate directly to their ability to follow medication regimens; unfortunately, many patients do not realise the extent of these problems, considering themselves able to take their own medicines even when they are unable [43]. Numerous limitations associated with progressive AD, including memory problems, polypharmacy, and physical problems, such as reading labels and swallowing difficulties, are all likely to have an impact on treatment adherence in AD [44, 45]. Additionally, many patients with AD also require medications for comorbid conditions, resulting in complex treatment regimens that are also known to decrease adherence [46].

In addition to physical limitations, the patient’s tolerability of any given agent may also affect adherence, with decreased adherence likely to result from poor drug tolerability [47]. The most common adverse events associated with all three of the oral ChEIs are gastrointestinal side effects [47]. The development of novel pharmacological treatments or applications for AD may improve drug tolerability. For example, it is reported that the risk for gastrointestinal adverse events is lower with transdermal rivastigmine than with the oral formulation [48].

Caregiver Factors

Family caregivers play a role in medication management from an early onset of AD [42]. However, older caregivers are themselves likely to be affected by a range of adherence factors common in the elderly population, such as polypharmacy, comorbid conditions and declining physical and visual abilities. As a result, elderly caregivers often experience difficulties with scheduling, administration and safety issues [8]. Indeed, one study reports that 12% of caregivers were estimated to have dementia themselves, with 20% treated for psychiatric conditions such as depression, a condition which is known to affect adherence to medication [8, 49]. Caregiver underestimation of patients’ cognitive impairments and overestimation of their ability to correctly administer their own medications, particularly in the early stages of disease, are also likely to impact on adherence [42]. Furthermore, given the burden and limitations faced by many caregivers, their personal preferences for dosing schedule and route of medication administration also have the potential to inadvertently impact on treatment adherence. As such, treatment schedules, such as once-daily dosing,
delivery routes that allow ease of administration are likely to be seen as advantageous. For example, >70% of caregivers have reported a preference for transdermal over oral delivery of rivastigmine [50–52].

Prescriber Factors
Prescriber factors that impact on unintentional treatment adherence in AD may include their compliance with published medical guidelines. Such adherence to medical guidelines is known to vary from country to country. For example, in the UK, uptake of new medications is slower than in many other countries; this is possibly owing to concerns about drug efficacy and safety [53]. Thus, new medications associated with better adherence may not be made available to all patients.

The frequency and quality of contact between the prescriber and the patient/caregiver are also major determinants of medication adherence, with good communication and frequent visits between patient and physician as a major factor for good adherence [8,40].

Interventions to Improve Adherence in AD

To date, strategies developed to increase treatment adherence in AD have focused on new drug delivery methods [54]. Concepts suggested include extended release, orally disintegrating or sublingual tablet formulations, intranasal or short- and long-acting intramuscular or transdermal forms, and nanotechnology-based delivery systems [54]. Of these, both extended-release tablets (galantamine) and transdermal application (rivastigmine) are already available. Donepezil is also available in a once-daily dosing formulation. Transdermal patch administration of rivastigmine has been shown to be of particular benefit compared with rivastigmine capsules because of increased tolerance, smooth and consistent drug delivery, easier access to optimal dose through simple titration steps, and the potential for improved efficacy at lower doses with this mode of administration [48,52,55,56]. It will be of interest to investigate how these strategies impact on patient and caregiver behaviour in the future.

Video home monitoring and reminder systems have also been tested as a means for improving compliance in cognitively impaired patients [57,58]. For example, in a cohort of 8 patients with mild dementia, those monitored using 2-way video technology demonstrated stable treatment adherence, whilst adherence in unmonitored patients decreased significantly over the treatment period [57]. However, these systems can be expensive and impractical to install and manage. Automated reminder devices may be easier to apply to the growing population of patients with AD, but do not have the benefit of increasing human contact with the patient [59].

Additional strategies to improve adherence to treatment in AD need to be developed and validated. These should focus on the specific patient, caregiver and prescriber factors that have been highlighted previously (table 2). We suggest that, in addition to the development of pharmacological strategies, interventions should also include education of physicians, patients and caregivers in order to address any unrealistic beliefs and expectations around the course of disease and benefits of any treatments. Particular emphasis should also be made to any cultural beliefs about AD, whilst the importance of treatment adherence should be stressed to both patient and caregiver. Good communication and frequent contact between patient, caregiver and physician is also of importance for all aspects of disease management.
Conclusions

By delaying the progression of AD symptoms, even for a few months, ChEIs can improve QoL for patients with AD and their caregivers. However, in order to achieve maximum benefit from these agents, as with any other medication, it is important that medication schedules are fully adhered to.

Important determinants of adherence to treatments in patients with AD include patient, caregiver and prescriber factors. Along with the physical, cognitive and psychological characteristics of caregivers and patients, their beliefs about AD and expectations about the efficacy of treatment may also be key determinants of adherence and should be addressed in any interventions aimed at improving it. The pharmacological development of ChEIs in order to improve treatment adherence, efficacy and tolerability has been reported in the literature. Consequently, a number of studies have reported on the benefits of transdermal drug delivery of rivastigmine in patients with AD. Further research is required to determine the extent to which such interventions improve adherence in this patient population.

Acknowledgements

R.B. is an employee of Atlantis Healthcare, and J.W. is a consultant for Atlantis Healthcare. Atlantis Healthcare was commissioned by Novartis to develop a carer support programme for patients prescribed the rivastigmine patch. Editorial assistance was provided by Fishawack Communications; this was funded by Novartis Pharma AG.

References


